AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01996865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01996865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Study NCT01996865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01996865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT04088071 — intervention group
Intervention type: DEVICE
Intervention: Catheter ablation
Description: Ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
Study NCT02926586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
Study NCT02926586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
Study NCT06622447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: βGluCnCs intervention
Description: The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into βGluCnCs intervention (N=40).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks.
Study NCT06622447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into placebo intervention (N=20).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks.
Study NCT01138137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles
Study NCT01138137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg
Study NCT01138137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles
Study NCT00509925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
Study NCT00509925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
Study NCT00509925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
Study NCT04299724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pathogen-specific aAPC
Description: The subjects will receive three injections of 5x10\^6 each Covid-19/aAPC vaccine via subcutaneous injections.
Study NCT00730210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a: PTH (1-84)
Description: preotact 100 microgram subcutaneous a day in 6 months
Study NCT02606006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Canine Animal-Assisted Therapy
Description: Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
Study NCT02606006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Physical Therapy
Description: This intervention is the standard of care physical therapy currently offered. No canine is present.
Study NCT04158895 — intervention group
Intervention type: OTHER
Intervention: Routine medical record data collection
Description: The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Study NCT03813784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
Study NCT03813784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
Study NCT03813784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
Study NCT03813784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
Study NCT03813784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
Study NCT03813784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
Study NCT02866149 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Up to 5 blood samplings can be performed at different time points
Study NCT01266694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicines
Description: oral form, 1 mg, once a day during 14 days
Study NCT01266694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral form, placebo
Study NCT00555022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1160724
Description: GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
Study NCT00555022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Description: Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
Study NCT02866149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Up to 5 blood samplings can be performed at different time points
Study NCT02866149 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor sampling
Description: One tumor sampling can be performed, if applicable
Study NCT02866149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor sampling
Description: One tumor sampling can be performed, if applicable
Study NCT02866149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stool sampling
Description: Up to 5 blood samplings can be performed at different time points
Study NCT00555022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo.
Study NCT01719601 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
Study NCT03207646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrightHeart®
Description: BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
Study NCT01129635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT) implantation
Description: The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.~Arm: CRT Candidate
Study NCT03204084 — intervention group
Intervention type: DEVICE
Intervention: Low-temperature Plasma Surgery System
Description: In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
Study NCT04068012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilator protocol
Description: open loop ventilator management by a computer based protocol
Study NCT02045862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: Participants received solifenacin 5 mg orally once a day at the same time each day.
Study NCT02045862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Participants received solifenacin 5 mg orally once a day at the same time each day.
Study NCT00755014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: red wine
Description: One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
Study NCT03129529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused shock wave
Description: The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
Study NCT03129529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial shock wave
Description: The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
Study NCT03241602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal lidocaine
Description: the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
Study NCT03241602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Recruitment
Description: pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
Study NCT03241602 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined intraperitoneal lidocaine and pulmonary recruitment maneuver
Description: the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
Study NCT03482856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MNA plus CBT-I
Description: MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
Study NCT03482856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MNA alone
Description: MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
Study NCT03245255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
Study NCT03176238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1
Study NCT03176238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: 25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1
Study NCT02623114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
Study NCT02623114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
Study NCT02974530 — intervention group
Intervention type: OTHER
Intervention: Neurological evaluation
Study NCT02974530 — intervention group
Intervention type: OTHER
Intervention: Laryngological evaluation
Study NCT02974530 — intervention group
Intervention type: OTHER
Intervention: MRI evaluation
Study NCT02974530 — intervention group
Intervention type: OTHER
Intervention: Breathing investigation
Study NCT02974530 — intervention group
Intervention type: OTHER
Intervention: MRI and articulatory investigation
Study NCT02974530 — intervention group
Intervention type: OTHER
Intervention: Postural investigation
Study NCT02045862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Participants received mirabegron 50 mg orally once a day at the same time each day.
Study NCT02974530 — intervention group
Intervention type: OTHER
Intervention: Voice and soundscape investigation
Study NCT00632008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soluble beta-glucan (SBG)
Description: Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
Study NCT02045862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants received mirabegron 50 mg orally once a day at the same time each day.
Study NCT00632008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
Study NCT00525603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200 mg/m\^2/day 3-5 IV 5-30 minutes
Study NCT00525603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 20 mg/m\^2/day 3-5 IV 5-30 minutes
Study NCT00525603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30 mg Days 1, 3, 5 IV 2-4 hours
Study NCT02045862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match solifenacin
Description: Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Study NCT02045862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match mirabegron
Description: Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Study NCT00525603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2/day 2 IV 4-6 hours
Study NCT03513601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R)-CHOP regimen
Description: (rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
Study NCT03513601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (R)-CVP regimen
Description: The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
Study NCT02459093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: poliglecaprone 25 suture
Description: cesarean delivery incision closure with poliglecaprone 25 suture
Study NCT02459093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyglactin 910 suture
Description: cesarean delivery incision closure with polyglactin 910 suture
Study NCT00650143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenograstim (GRANOCYTE)=GCSF
Description: 10 µg/kg/d s.c. for 5 days divided in two dosages per day
Study NCT00650143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin (Januvia)
Description: 100 mg p.o. per day for 28 days
Study NCT00650143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride (NaCl) 0.9 %
Description: applied s.c. twice a day for 5 days
Study NCT00650143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin
Description: One capsule p.o. per day for 28 days
Study NCT04598893 — intervention group
Intervention type: BIOLOGICAL
Intervention: Teplizumab
Description: Received teplizumab in PROTECT Study
Study NCT04598893 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Received placebo in PROTECT study
Study NCT03386955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711 Capsule
Description: Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
Study NCT00119925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient education
Description: patient leaflets about national guideline contents
Study NCT00119925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: professional audit and feedback (guideline adherence)
Description: feedback on current practice according to quality indicators
Study NCT00119925 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: professional education (communication/shared decision making)
Description: educational tools for professionals concerning communication and shared decision making
Study NCT00119925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information tools
Description: tools and checklists to improve information provision
Study NCT00383240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
Study NCT00383240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate MDI (MF MDI) 200 mcg
Description: MF 200 mcg via metered dose inhaler twice daily for 26 weeks
Study NCT00383240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol fumarate 10 mcg
Description: F via metered dose inhaler 10 mcg twice a day for 26 weeks
Study NCT00383240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo metered dose inhaler twice a day for 26 weeks
Study NCT04187391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.
Study NCT04187391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS anode is applied over the left DLPFC with the cathode over the right supraorbital region.